Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 401–500 of 1,005
Guedeney, P., Claessen, B. E., Kalkman, D. N., Aquino, M., Sorrentino, S., Giustino, G., Farhan, S., Vogel, B., Sartori, S., Montalescot, G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.077 · Cited by 129
Current concepts and novel targets for antiplatelet therapy
Gawaz, M., Geisler, T., & Borst, O. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00854-6 · Cited by 148
Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?
Schömig, A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0906549 · Cited by 130
Gebremeskel, S., LeVatte, T. L., Liwski, R., Johnston, B., & Bezuhly, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28947 · Cited by 138
James, S. K., Storey, R. F., Khurmi, N. S., Husted, S., Keltai, M., Mahaffey, K. W., Maya, J. F., Morais, J., Lópes, R. D., Nicolau, J. C., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.082727 · Cited by 129
Self-citationKwok, C. S., Khan, M. A., Rao, S. V., Kinnaird, T. D., Sperrin, M., Buchan, I. E., de Belder, M., Ludman, P., Nolan, J., Loke, Y. K., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001645 · Cited by 128
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
Storey, R. F., Angiolillo, D. J., Bonaca, M. P., Thomas, M. R., Judge, H. M., Rollini, F., Franchi, F., Ahsan, A. J., Bhatt, D. L., Kuder, J. F., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.062 · Cited by 128
Self-citationKleinbongard, P., Bøtker, H. E., Ovize, M., Hausenloy, D. J., & Heusch, G. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14839 · Cited by 135
“…effect of ticagrelor is involved in the mechanisms underlying its superior effect over that of clopidogrel in patients with acute myocardial infarction (Wallentin et al., 2009), including those with or without ST elevation who undergo planned revascularization (Cannon et al., 2010).”
BackgroundAngiolillo, D. J., Galli, M., Alexopoulos, D. K., Aradi, D., Bhatt, D. L., Bonello, L., Capodanno, D., Cavallari, L. H., Collet, J., Cuisset, T., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.08.027 · Cited by 157
Self-citationPathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments
Montecucco, F., Carbone, F., & Schindler, T. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv592 · Cited by 143
Management of Antithrombotic Therapy after Acute Coronary Syndromes
Rodríguez, F., & Harrington, R. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1607714 · Cited by 144
Self-citationIbrahim, K. S., Christoph, M., Schmeinck, S., Schmieder, K., Steiding, K., Schoener, L., Pfluecke, C., Quick, S., Mues, C. A., Jellinghaus, S., et al. (2014) · Resuscitation · doi:10.1016/j.resuscitation.2014.02.004 · Cited by 130
Kazi, D. S., Leong, T. K., Chang, T. I., Solomon, M. D., Hlatky, M. A., & Go, A. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.047 · Cited by 127
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Ali, A. S., Brady, W. J., Ghaemmaghami, C. A., Menon, V., Welsford, M., & Shuster, M. (2015) · Circulation · doi:10.1161/cir.0000000000000263 · Cited by 145
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Protective Effects of Ticagrelor on Myocardial Injury After Infarction
Vilahur, G., Gutiérrez, M., Casaní, L., Varela, L. M., Capdevila, A., Pons‐Lladó, G., Carreras, F., Carlsson, L. G., Hidalgo, A., & Badimón, L. (2016) · Circulation · doi:10.1161/circulationaha.116.024014 · Cited by 128
Dayoub, E. J., Seigerman, M. E., Tuteja, S., Kobayashi, T., Kolansky, D. M., Giri, J. S., & Groeneveld, P. W. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0783 · Cited by 133
Chin, C. T., Roe, M. T., Fox, K. A. A., Prabhakaran, D., Marshall, D. A., Petitjean, H., Lokhnygina, Y. V., Brown, E., Armstrong, P. W., White, H. D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.022 · Cited by 123
Angiolillo, D. J. (2012) · Drugs · doi:10.2165/11640880-000000000-00000 · Cited by 134
Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators
Her, L., & Zhu, H. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089680 · Cited by 131
Aspirin and antiplatelet treatments in cancer
Tao, D. L., Yunga, S. T., Williams, C. D., & McCarty, O. J. T. (2021) · Blood · doi:10.1182/blood.2019003977 · Cited by 133
Ye, Y., Birnbaum, G. D., Perez-Polo, J. R., Nanhwan, M. K., Nylander, S., & Birnbaum, Y. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305655 · Cited by 125
Dangas, G., Claessen, B. E. P. M., Mehran, R., Xu, K., Fahy, M. P., Parise, H., Henriques, J. P. S., Ohman, E. M., White, H. D., & Stone, G. W. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.07.012 · Cited by 121
Coronary stents: factors contributing to perioperative major adverse cardiovascular events
Barash, P. G., & Akhtar, S. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq318 · Cited by 121
The Role of Clopidogrel in 2020: A Reappraisal
Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/8703627 · Cited by 151
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.015 · Cited by 127
Baber, U., Dangas, G., Cohen, D. J., Gibson, C. M., Mehta, S. R., Angiolillo, D. J., Pocock, S., Krucoff, M. W., Kastrati, A., Ohman, E. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.006 · Cited by 125
Self-citationAtherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly
Violi, F., Loffredo, L., Carnevale, R., Pignatelli, P., & Pastori, D. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6963 · Cited by 118
“The PLATO study (391) included 18,624 patients with ACS without ST segment elevation, to compare the efficacy of ticagrelor versus clopidogrel during a follow-up of 30 days.”
Wiviott, S. D., Antman, E. M., & Braunwald, E. (2010) · Circulation · doi:10.1161/circulationaha.109.921502 · Cited by 122
Siller-Matula, J. M., Krumphuber, J., & Jilma, B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00555.x · Cited by 116
Turgeon, R. D., Koshman, S. L., Youngson, E. R. E., Har, B., Wilton, S. B., James, M. T., & Graham, M. M. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.6447 · Cited by 121
“Patients filled their first outpatient prescription for a P2Y12 inhibitor a median (interquartile range) of 3 (1-4) days after Research Original Investigation Ticagrelor vs Clopidogrel and Major Adverse Coronary Events in Acute Coronary Syndrome”
MethodWallentin, L., Lindholm, D., Siegbahn, A., Wernroth, L., Becker, R. C., Cannon, C. P., Cornel, J. H., Himmelmann, A., Giannitsis, E., Harrington, R. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004420 · Cited by 116
Self-citationPart 9: Acute Coronary Syndromes
O’Connor, R. E., Bossaert, L. L., Arntz, H.-R., Brooks, S. C., Diercks, D., Feitosa-Filho, G. S., Nolan, J. P., Hoek, T. L. V., Walters, D., Wong, A., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.985549 · Cited by 121
Patti, G., Pasceri, V., Vizzi, V., Ricottini, E., & Sciascio, G. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.025 · Cited by 120
Iannaccone, M., D’Ascenzo, F., Vadalà, P., Wilton, S. B., Noussan, P., Colombo, F., Raposeiras‐Roubín, S., Assi, E. A., González‐Juanatey, J. R., Henriques, J. P. S., et al. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617706501 · Cited by 135
From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion
Młynarska, E., Czarnik, W., Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137295 · Cited by 191
“Based on trial results, dual-antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor is recommended for patients with ACS [97,98].”
BackgroundAnti‐platelet therapy: ADP receptor antagonists
Wijeyeratne, Y. D., & Heptinstall, S. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03999.x · Cited by 120
Nikolic, E., Janzon, M., Hauch, O., Wallentin, L. C., Henriksson, M., & for the PLATO Health Economic Substudy Group (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs149 · Cited by 114
Self-citationUnstable Angina and Non–ST Elevation Myocardial Infarction
Braunwald, E. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1745ci · Cited by 127
Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
Siller-Matula, J. M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle‐Karth, G., Gouya, G., Ruzicka, K., Podczeck-Schweighofer, A., & Christ, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.040 · Cited by 114
Gurbel, P. A., & Tantry, U. S. (2012) · Circulation · doi:10.1161/circulationaha.111.031195 · Cited by 120
Acute coronary syndrome in the Asia-Pacific region
Chan, M. Y., Du, X., Eccleston, D. S., Ma, C., Mohanan, P. P., Ogita, M., Shyu, K., Yan, B. P., & Jeong, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.073 · Cited by 128
Casselman, F. P. A., Lance, M. D., Ahmed, A. B., Ascari, A., Blanco-Morillo, J., Bolliger, D., Eid, M., Erdoes, G., Haumann, R. G., Jeppsson, A., et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae352 · Cited by 187
New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention
Bellemain-Appaix, A., Brieger, D. B., Beygui, F., Silvain, J., Peña, A., Cayla, G., Barthélémy, O., Collet, J., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.012 · Cited by 112
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Montalescot, G., Brieger, D. B., Dalby, A. J., Park, S., & Mehran, R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.053 · Cited by 115
Perioperative management of antiplatelet therapy
Oprea, A. D., & Popescu, W. M. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet402 · Cited by 121
Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock
Vandenbriele, C., Arachchillage, D. J., Frederiks, P., Giustino, G., Gorog, D. A., Gramegna, M., Janssens, S. P., Meyns, B. P., Polzin, A., Scandroglio, M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.052 · Cited by 113
Kang, H., Clare, R. M., Gao, R., Held, C., Himmelmänn, A., James, S. K., Lim, S. T., Santoso, A., Yu, C., Wallentin, L. C., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.015 · Cited by 115
Self-citationNylander, S., & Schulz, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13429 · Cited by 114
Escaned, J., Cao, D., Baber, U., Nicolas, J., Sartori, S., Zhang, Z., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab702 · Cited by 119
Sillén, H., Cook, M., & Davis, P. C. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.06.018 · Cited by 110
Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A. A., Armstrong, P. W., Prabhakaran, D., Hafley, G. E., Lokhnygina, Y. V., Boden, W. E., Hamm, C. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61451-8 · Cited by 116
Antithrombotic therapy for patients with STEMI undergoing primary PCI
Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.18 · Cited by 115
Álvarez‐Pedrerol, M., Rivas, I., López-Vicente, M., Suades-González, E., Donaire-González, D., Cirach, M., de Castro, M., Esnaola, M., Basagaña, X., Dadvand, P., et al. (2017) · Environmental Pollution · doi:10.1016/j.envpol.2017.08.075 · Cited by 127
Tarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.053 · Cited by 121
Schulz, S., Richardt, G., Laugwitz, K., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A., Tölg, R., Fiedler, K. A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu182 · Cited by 108
Cohen, M. V., & Downey, J. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12903 · Cited by 120
Faxon, D. P., Eikelboom, J. W., Berger, P. B., Holmes, D. R., Bhatt, D. L., Moliterno, D. J., Becker, R. C., & Angiolillo, D. J. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.111.965186 · Cited by 108
Self-citationSorbets, E., Fox, K. M., Elbez, Y., Danchin, N., Dorian, P., Ferrari, R., Ford, I., Greenlaw, N., Kalra, P. R., Parma, Z., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz660 · Cited by 108
Self-citationImpact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Généreux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., Angiolillo, D. J., Price, M. J., Prats, J., LaSalle, L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.022 · Cited by 107
Self-citationInefficacy of Platelet Transfusion to Reverse Ticagrelor
Godiér, A., Taylor, G., & Gaussem, P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1409373 · Cited by 107
Management of cardiovascular disease in patients with kidney disease
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15 · Cited by 115
Tanguay, J., Bell, A., Ackman, M. L., Bauer, R. D. C., Cartier, R., Chan, W., Douketis, J. D., Roussin, A., Schnell, G., Verma, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.001 · Cited by 105
Vranckx, P., Valgimigli, M., Windecker, S., Steg, P. G., Hamm, C. W., Jüni, P., García‐García, H. M., van Es, G., & Serruys, P. W. J. C. (2016) · EuroIntervention · doi:10.4244/eijy15m11_07 · Cited by 109
Self-citationInterventions for lower extremity peripheral artery disease
Hiramoto, J. S., Teraa, M., de Borst, G. J., & Conte, M. S. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0005-0 · Cited by 114
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.006 · Cited by 118
Bonaca, M. P., Bhatt, D. L., Braunwald, E., Cohen, M. C., Steg, P. G., Storey, R. F., Held, P. H., Jensen, E. C., & Sabatine, M. S. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.020 · Cited by 109
Self-citationCurrent concepts on coronary revascularization in diabetic patients
Roffi, M., Angiolillo, D. J., & Kappetein, A. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr305 · Cited by 105
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI
Marquis‐Gravel, G., Dalgaard, F., Jones, A. D., Lokhnygina, Y. V., James, S. K., Harrington, R. A., Wallentin, L. C., Steg, P. G., Lópes, R. D., Storey, R. F., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.031 · Cited by 116
Self-citationSzummer, K. E., Montez‐Rath, M. E., Alfredsson, J., Erlinge, D., Lindahl, B., Hofmann, R., Ravn‐Fischer, A., Svensson, P., & Jernberg, T. (2020) · Circulation · doi:10.1161/circulationaha.120.050645 · Cited by 122
“For each of the bootstrap samples, the above analysis was performed: (1) impute 5 datasets; (2) in each, estimate the probability of treatment, calculate IPTW weights, and run a weighted Cox regression model; (3) average the 5 coefficients to obtain an estimate for the bootstrap sample.”
MethodWhite, H. D., Chew, D. P., Dauerman, H. L., Mahaffey, K. W., Gibson, C. M., Stone, G. W., Gruberg, L., Harrington, R. A., & Bhatt, D. L. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.001 · Cited by 107
Self-citationCost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Kazi, D. S., Garber, A. M., Shah, R. U., Dudley, R. A., Mell, M. W., Rhee, C., Moshkevich, S., Boothroyd, D. B., Owens, D. K., & Hlatky, M. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1999 · Cited by 108
Gurbel, P. A., Fox, K. A. A., Tantry, U. S., Cate, H. T., & Weitz, J. I. (2019) · Circulation · doi:10.1161/circulationaha.118.033580 · Cited by 111
Mitsis, A., & Gragnano, F. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999201210195702 · Cited by 138
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E. A. A., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70033-2 · Cited by 109
Li, Y., Tang, H., Hu, Y., & Xie, H. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04570.x · Cited by 103
Lancellotti, P., Musumeci, L., Jacques, N., Servais, L., Goffin, E., Pirotte, B., & Oury, C. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1189 · Cited by 103
Frailty and cardiovascular mortality in more than 3 million US Veterans
Shrauner, W. R., Lord, E. M., Nguyen, X. T., Song, R. J., Galloway, A., GAGNON, D. R., Driver, J. A., Gaziano, J. M., Wilson, P. W. F., Djoussé, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab850 · Cited by 117
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease
Gurbel, P. A., Bliden, K. P., Turner, S. E., Tantry, U. S., Gesheff, M. G., Barr, T. P., Covic, L., & Kuliopulos, A. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306777 · Cited by 116
Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., Johnston, S. C., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.032239 · Cited by 102
Self-citationNeubauer, H. P., Kaiser, A. F., Endres, H. G., Krüger, J. C., Engelhardt, A., Lask, S., Pepinghege, F., Kusber, A., & Mügge, A. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-3 · Cited by 112
P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation
Mansour, A., Bachelot‐Loza, C., Nesseler, N., Gaussem, P., & Gouin‐Thibault, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041391 · Cited by 113
P2Y12 receptor in platelet activation
Kim, S., & Kunapuli, S. P. (2011) · Platelets · doi:10.3109/09537104.2010.497231 · Cited by 101
The evolution of antiplatelet therapy in cardiovascular disease
Yousuf, O. K., & Bhatt, D. L. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.96 · Cited by 114
Damman, P., Beijk, M. A. M., Kuijt, W. J., Verouden, N., van Geloven, N., Henriques, J. P. S., Baan, J., Vis, M. M., Meuwissen, M., van Straalen, J. P., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.053 · Cited by 103
Berger, J. S., Roe, M. T., Gibson, C. M., Kilaru, R., Green, C. L., Melton, L. G., Blankenship, J., Metzger, D. C., Granger, C. B., Gretler, D. D., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.10.010 · Cited by 100
Self-citationLewis, J. P., Backman, J., Reny, J., Bergmeijer, T. O., Mitchell, B. D., Ritchie, M. D., Déry, J., Pakyz, R. E., Gong, L., Ryan, K. A., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz045 · Cited by 100
“Given its effectiveness and cost, clopidogrel continues to be used frequently compared to newer alternatives such as prasugrel and ticagrelor.(2,3) However, substantial inter-individual variability in clopidogrel response exists, and patients who experience sub-optimal therapy have high ontreatment platelet reactivity…”
BackgroundNahrendorf, M., & Swirski, F. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv453 · Cited by 95
Patel, M. R., Becker, R. C., Wojdyla, D. M., Emanuelsson, H., Hiatt, W. R., Horrow, J., Husted, S., Mahaffey, K. W., Steg, P. G., Storey, R. F., et al. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487314533215 · Cited by 99
Self-citationBonaca, M. P., Bhatt, D. L., Ophuis, T. O., Steg, P. G., Storey, R. F., Cohen, M. C., Kuder, J., Im, K., Magnani, G., Budaj, A., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1017 · Cited by 100
Self-citationCao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 104
Emerging roles of thioredoxin cycle enzymes in the central nervous system
Patenaude, A., Murthy, M. R. V., & Mirault, M.-É. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4541-5 · Cited by 112
Patti, G., Caterina, R. D., Abbate, R., Andreotti, F., Biasucci, L. M., Calabrò, P., Cioni, G., Davì, G., Sciascio, G. D., Golia, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu279 · Cited by 101
Interpreting Geographic Variations in Results of Randomized, Controlled Trials
Yusuf, S., & Wittes, J. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510065 · Cited by 104
Gorog, D. A., Ferreiro, J. L., Ahrens, I., Ako, J., Geisler, T., Halvorsen, S., Huber, K., Jeong, Y., Navarese, E. P., Rubboli, A., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00901-2 · Cited by 111
“Approved regimens of prasugrel and ticagrelor achieve a higher mean level of platelet inhibition than clopidogrel 25–27 and are associated with higher rates of minor and major bleeding 9,10,28–30 (Table 2).”
BackgroundSelf-citation2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Self-citationSilvain, J., Abtan, J., Kernéis, M., Martin, R., Finzi, J., Vignalou, J.-B., Barthélémy, O., O’Connor, S. A., Luyt, C. E., Bréchot, N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.029 · Cited by 98
Fanning, J. P., Nyong, J., Scott, I. A., Aroney, C. N., & Walters, D. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004815.pub4 · Cited by 98
Bellemain-Appaix, A., Kernéis, M., O’Connor, S. A., Silvain, J., Cucherat, M., Beygui, F., Barthélémy, O., Collet, J. ‐., Jacq, L., Bernasconi, F., et al. (2014) · BMJ · doi:10.1136/bmj.g6269 · Cited by 101
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
Bhatt, D. L., Hulot, J., Moliterno, D. J., & Harrington, R. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302737 · Cited by 102
Self-citation
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.